(Reuters) -ADC Therapeutics said on Tuesday it had paused enrollments in a mid-stage study evaluating its drug Zynlonta for treating a type of blood cancer over safety concerns.
The company’s U.S.-listed shares tumbled about 18% in premarket trading.
ADC said it paused the enrolment after the review of data of 40 patients in the trial signaled potentially excessive respiratory-related events, including seven deaths and five serious adverse events.
The cause of these events remains under further investigation, the company said.
(Reporting by Raghav Mahobe in Bengaluru; Editing by Sriraj Kalluvila)
